The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
20% drop before lunch is not a shake. We are now in high risk high reward territory
Don' t rush Mugsy.
Ok, I'm back and feeling refreshed.
Did I miss anything?
To be honest it is starting to get to me a bit now.
I think I need to take a break from the board until I get over the impact that these things have on me psychologically. I'll be back once I recover!
Sam they don't need to change the software the Genedrive software is an upgrade that's all its not required to run the test! Current platforms will work
GAZAL
Agree about BigBite
Mugsy hates his popularity, that's why he tries unsuccessfully to find fault.
He tries it with anyone who gets a significant number of votes up for a post. He can't handle it.
Small man syndrome.
@RBInvests As is your prerogative but your response only goes to further my conviction that you are oversimplifying the comparison, although you are not alone.
I have lost count as to how many times I see AVCT, GDR and NCYT all thrown into the same discussion, like they are similar or something. The only similarity is that they are involved in the covid pandemic market, to varying degrees.
I will however say it one last time, GDR is aiming for a segment of the market that to date, has barely been accessed and in part, cannot be properly accessed by NCYT, however many sales they confirm to the market.
I'm not in GDR but used to be.
Just wanted to praise BigBiteNow for his posts on this thread.
You don't half post some great stuff. My hat goes off to you.
Ignore lb28 - he probably is heavily down and needs this to spike. In his world all is good and there are zero issues with gdr. If you challenge to to look at the facts he'll just throw bad language at you and tell you that you ate wrong. Ignore or filter him.
@samolly2 I appreciate that and I sympathise greatly with those that are heavily under water on their investments here but simply making things up like "so they had CE approval and were expecting g significant sales in june," only services those that would wish to see GDR fail.
For the record, I am not gutted.
Covid testing is a far longer term play than many see fit to accept. The target markets that GDR are aiming for, will likely be the longest term markets for Covid testing, for those tests that are best equipped for their markets and provide competitive advantages.
People go on about NCYT as if its a 2 horse race. GDR don't need to replace what NCYT is doing, they need to replace the large percentage of tests that simply don't do their prescribed job. That unfortunately takes time but this market and the majority of this BB, simply don't want to give the GDR team time to execute. This is based on a ticking timer that in in most people's heads only.
The current Oxford/Astra Zenica vaccine trial that is being conducted in South Africa, is required to confirm its suitability for lower/middle income countries. The lead scientist has stated that when everything goes well, the vaccine wold be available to the S.A. market by Sept/Oct 2021. That's the beginning of roll out. That's not Africa, that's S.A.
That assumes that this first trial vaccine manages to provide 70% herd immunity. The average success rate of the influenza vaccine in the last 10 years is 50%. 50% doesn't cut it unfortunately.
There have been years when efficacy rate was as low as 10%. The first vaccine candidate has to have a heck of a lot go right for it and even then it highly likely won't be effectively distributed before 2022.
If successful then the vaccine comes to Europe first of all, closely followed by the US. It is still highly unlikely going to give herd immunity and so testing will still be required, longer term, be it at reduced levels. That's where better quality tests will earn their crust and when price sensitivity will likely finally kick in.
Realistically testing is not going away as long as Covid itself decides to stick around. So GDR has time and its target markets driven by its storage advantages, stand it in very good stead, post regulatory approvals.
LB28, why are you getting so emotive about things? I'm not criticising your family or suchlike, merely passing comment on a business that we both have shares in. When you get that emotional about protecting a paper investment, time to question that investment.
I was crying, I still haven't stopped. You can't even begin to imagine how much the ordeal has impacted my self confidence.
As an aside, remember that time that you thought that indicative orders = sales? lol
Mugsy
You don't have the minerals to 'debate'.
You cry and protest when someone filters you and then cry again to get the post removed that highlights it.
You lack self confidence and it all becomes about 'you' rather than about the investment.
BBN
I don't see GDR as a direct competitor to NCYT, not anymore. One is an established player that is generating profits and in a prime position to take a large slice out of the current market and future markets.. The other is not. Hence why I've moved funds from one to the other. Simples.
BBN, can we continue our 'debate' on whether we have any finalised sales?
RBInvest Why do you believe that NCYT is a direct competitor in all of GDRs target markets? Why is it you appear to believe that GDR cannot succeed simply because NCYT exist? Why is it a competition at all?
There is currently a world shortage of adequate testing capacity. That is before we begin to discuss quality testing. If NCYT has it all covered, then why does that shortage continue to exist?
Why is the NCYT Covid test not dominating the Indian market? highly ,likely because it cannot be stored at room temperature. Therefore, it is only suitable for roll out in areas where adequate refrigeration exists. It is generally not suitable for all other areas of which there are clearly many in India and many people live there.
From the now validated DIVOC site ;
"The Genedrive® 96 SARS-CoV-2 kit is stable at ambient temperatures which eliminates the need for cold
storage, making the test very practical for Indian markets. Given its ease of use and temperature stability, the kit can be employed in remote and rural areas."
The same applies for Africa, hence the GDR focus on those areas. Those areas require time to be exploited. They are generally slower at doing things. That cannot be helped.
The NCYT kit cannot do that. So its not about merely handing out contracts, its about what each particular contract's aim is and where it is situated.
Thanks LB28, very constructive. Please, let us hear your thoughts. Blind faith over bald facts. Boat missed.
Love how you insult others LB28.
When do you think they will announce these finalised sales that they are keeping a secret from us?
Fact of the matter is that GDR have no track record, NCYT has been producing £10Ms of revenue for the past months and GDR nothing. If you're handing out contracts right now, who do you hand them to? It's like comparing apples and oranges, from both a commercial and investment point of view. Boat missed.
It’s now a case of where the exit point is
Yep. Too late. Which is what I said 6 weeks ago but stayed in against my better judgment. Paying the price now. Looks like I was right in this all along. I think we are deluded that big things are coming here. There is clearly just no appetite for what they’ve made. A good standard isn’t what’s needed. Companies and governments will just want the cheapest test that does the job.
CE mark means fck all apparently
Does the CE Mark not mean that we are eligible to be included for consideration for Part of the government £5bil?
The company seems to be more interested in chasing down Africa, India, USA where we will need authorisation.
But the UK is fair game under CE I thought?
Hi, you have revenue of 1M in July, but there is no revenue in July. Indicative orders do not give revenue. I've seen a potential 7 week wait for approvals, so that writes off August revenues too. You cannot shift stock and invoice until approved. Your revenue estimations therefore have to start from September.
My fear is that, having waited for approvals, it's too late. Too late to get a seat at the WHO table, too late to have got a slice of the the UK's 5B pie.....just too late.
Yeah, I know, on the face of it what you suggest does some conservative in theory but I am just not convinced yet how it will go in practice. Things are moving more slowly that DB expected and I just worry that this additional time will not only cut our potential market share but in some cases eliminate us entirely as an option.
Once the first few sales updates come in, based on their size and regularity, let's revisit the figures.